Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Veru (VERU)
NASDAQ:VERU
Holding VERU?
Track your performance easily
Earnings Data
Report Date
Feb 05, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.08Last Year’s EPS
-0.08Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Dec 13, 2018
|% Change Since: 27.27%
|Next Earnings Date:Aug 14, 2018
Earnings Call Sentiment|Neutral
The call presented a mix of positive developments, such as significant progress in clinical trial enrollment and financial management, alongside ongoing challenges like declining prescription business revenue and sustained net losses. Despite these challenges, the overall momentum and strategic advancements suggest cautious optimism.Company Guidance
During the Q3 2024 earnings call for Veru Inc., the company provided several key metrics and updates on their clinical and financial progress. Veru highlighted its focus on developing Enobosarm in combination with Wegovy, aiming to preserve muscle mass and enhance fat loss for higher quality weight management. In terms of financials, Veru reported net revenues of $4 million, a 21% increase from the previous year's third quarter, with gross profit at $1.3 million or 34% of net revenues. Operating expenses decreased to $12.4 million from $19.7 million in the prior year, primarily due to reduced research and development costs. The company ended the quarter with $29.2 million in cash, which they believe will be sufficient to complete ongoing clinical trials. Moreover, Veru has completed enrollment for a Phase IIb study with 150 participants, with top-line results expected by January 2025. The call also revealed plans to present new clinical data at upcoming conferences, underscoring Veru's commitment to advancing its drug development pipeline.Completion of Patient Enrollment for Phase IIb Study
Veru Inc. successfully completed enrollment of over 150 patients for its Phase IIb quality clinical study, with results expected in January 2025.
Financial Performance Highlights
Net revenues increased to $4 million from $3.3 million year-over-year for the quarter ending June 30, 2024. Operating expenses decreased significantly to $12.4 million from $19.7 million in the prior year's quarter.
Strong Cash Position
The company ended the quarter with $29.2 million in cash, up from $9.6 million as of September 2023, and anticipates having sufficient resources to complete ongoing clinical trials.
Phase IIb Study Expansion
The study was upsized to 150 patients to increase the power of the study, reflecting strategic planning and confidence in the trial's potential outcomes.
---
VERU Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
VERU Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Aug 08, 2024 | $0.77 | $0.81 | +5.19% |
| May 08, 2024 | $1.63 | $1.43 | -12.27% |
| Feb 08, 2024 | $0.44 | $0.41 | -6.82% |
| Dec 14, 2023 | $0.83 | $0.75 | -9.64% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Veru (VERU) report earnings?
Veru (VERU) is schdueled to report earning on Feb 05, 2025, TBA Not Confirmed.
What is Veru (VERU) earnings time?
Veru (VERU) earnings time is at Feb 05, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is VERU EPS forecast?
VERU EPS forecast for the fiscal quarter 2025 (Q1) is -0.08.
---